Introduction - 13/08/13
Funding: The publication of this manuscript was funded by Novo Nordisk Inc. |
|
Conflict of Interest: REP has received Research/Clinical Trial Support from GlaxoSmithKline, Lilly, Mannkind, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; and has attended Advisory Panel/acted as a Consultant or Speaker for AstraZeneca/Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Lexicon, Mannkind, Merck, Novo Nordisk, Novartis, Roche, Sanofi, and Takeda. As of June 2011, all honoraria are directed to a nonprofit foundation. |
|
Authorship: The author takes full responsibility for the content of this manuscript. Writing support was provided by Watermeadow Medical. |
Vol 126 - N° 9S1
P. S1 - septembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?